Short Interest in Kamada Ltd. (NASDAQ:KMDA) Expands By 8.9%

Kamada Ltd. (NASDAQ:KMDA) was the recipient of a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 29,300 shares, a growth of 8.9% from the October 31st total of 26,900 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average daily volume of 34,400 shares, the days-to-cover ratio is currently 0.9 days.

Analyst Upgrades and Downgrades

KMDA has been the subject of a number of analyst reports. StockNews.com downgraded shares of Kamada from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 27th. HC Wainwright reiterated a “buy” rating and set a $11.00 price target on shares of Kamada in a report on Thursday, November 14th.

Kamada Price Performance

Shares of Kamada stock opened at $5.96 on Wednesday. Kamada has a 1 year low of $4.66 and a 1 year high of $6.53. The company has a market capitalization of $342.58 million, a price-to-earnings ratio of 21.29 and a beta of 0.99. The business has a fifty day simple moving average of $5.59 and a two-hundred day simple moving average of $5.49.

Institutional Trading of Kamada

Hedge funds and other institutional investors have recently modified their holdings of the stock. Public Employees Retirement System of Ohio bought a new stake in Kamada in the 3rd quarter valued at $77,000. Plato Investment Management Ltd bought a new stake in shares of Kamada in the third quarter valued at about $117,000. Y.D. More Investments Ltd grew its stake in shares of Kamada by 1,956.0% in the second quarter. Y.D. More Investments Ltd now owns 726,161 shares of the biotechnology company’s stock valued at $3,643,000 after acquiring an additional 690,842 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in Kamada by 8.2% during the first quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock worth $7,433,000 after acquiring an additional 100,800 shares during the period. Institutional investors own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.